Pathology Diagnostics Ltd (PDL) Presence at Dako Symposium Strengthens Industry Connections
Online, July 3, 2014 (Newswire.com) - A delegation of senior technical management staff from Pathology Diagnostics Ltd attended the recent Dako Link-UP Scientific Symposium held in York in late June 2014. Their presence strengthened good connections already in place with Dako staff, and highlighted similarities in quality control and auditing needs with NHS institutes.
The introduction of ISO15189 aims to reduce the uncertainty in laboratory testing, and even though it is focused more towards best-practice within NHS hospitals environs, Pathology Diagnostics Ltd aims to follow its stringent criteria within its industry accredited quality management system and take measures to continue to enhance its quality control through CAPA monitoring.
The overall 'take home' message from the symposium is that to reduce uncertainty in the field of Histopathology, there must be a significant increase in quality control across more organisations (both public and private) within the scientific research community.
Notes to editors and media:
Pathology Diagnostics Ltd is an independent GCLP accredited histopathology research organisation delivering high quality tissue laboratory & diagnostics services to industry Research & Development scientists engaged in drug and biomarker development.
Specialising in the provision of clinical diagnostics and quantitative image analysis on human tissues for studies ranging from early discovery to clinical trials, Pathology Diagnostics Ltd offers a range of services from traditional histopathology techniques to advanced digital pathology, whole slide scanning, central biorepository services and quantitative image analysis of biomarkers.
Dako is owned by Agilent Technologies. Hospitals and research laboratories worldwide use Agilent's Dako reagents, instruments, software and expertise to make accurate tissue-based diagnoses and determine the most effective treatment for cancer patients.